Table of Contents

Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview and Potential

• • Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2019-2030 (Dermatological, Cardiovascular-Blood, Oncology, Ophthalmic, Musculoskeletal, Other Conditions)

Coronavirus Cell and Gene Therapy Pipeline

Chapter 2: Introduction to Cell and Gene Therapy
Introduction

• Cell Therapy
  • Table 2-1: Adult vs. Embryonic Stem Cells
• Gene Therapy
  • Table 2-2: Somatic vs. Germ Line Gene Therapy
• Viral Vector System and New Developments
  • Table 2-3: Examples of Viruses in Gene Therapy
  • Figure 2-1: Gene Therapy Vector Type Distribution, Commercialized (current and former) Products (%) (Retrovirus and Gamma-Retrovirus, Lentiviral, Non-viral, Herpes Simplex Virus, Adeno and Adeno-associated Virus)
• Non-viral Systems for Transporting Genes
• Gene Editing

Cell and Gene Therapy: Characteristics

• • Table 2-4: Cell Therapy vs. Gene Therapy
• • Table 2-5: Autologous vs. Allogeneic Cell and Gene Therapies, Commercialized Products
• • Figure 2-2: Cell and Gene Therapy, Autologous and Allogeneic Distribution for Commercialized Products (%)
• • Figure 2-3: Cell and Gene Therapy (combined autologous and allogeneic), Route of Administration Distribution for Commercialized Products (%) (Topical, Implant, Intravenous, Injection)

Staffing
Manufacturing Process for CAR-T

• Leukapheresis
• Activation
• Transduction
• Expansion

Advancements and Barriers in Manufacturing Processes

• • Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
• • Figure 2-4: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)

Cost
Reimbursement
Logistics
Mergers and Acquisitions

• • Table 2-7: Select Company Mergers and Acquisitions in the Cell and Gene Therapy Market

Regulatory Developments

• Fast Track
• Orphan Drug
• Breakthrough Therapy
• Accelerated Approval
• Priority Review
  • Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country
• Individualized Gene Therapy Approval Process

Development and Pipeline Overview
Development Progress

• • Figure 2-5: Global Cell and Gene Therapy Development Progress (phase I through phase III)
• • Figure 2-6: Global Cell and Gene Therapy Development Progress by Phase (%)

Development by Condition/Disorder

• • Figure 2-7: Global Development of Cell and Gene Therapies by Target (%) (Oncology; Genetic disorders; Hematology; Immunology; Endocrine, metabolic; Cardiovascular; Musculoskeletal disorders; Infectious disease; Ophthalmology; Gastroenterology; Respiratory; Dermatology; Neurology; Other disorders)

Phase III Development

• • Table 2-9: Phase III Development æ Cell and Gene Therapies, Select Projects
• • Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)

End User

• Hospitals
• Research Institutes
• Wound Care Centers
• Cancer Centers

Chapter 3: Cell and Gene Therapy Markets in Dermatology
Overview

• • Table 3-1: Wound Prevalence by Type

Market Outlook

• • Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2019-2030 ($ millions)

Principal Products

• Apligraf
• CureSkin
• Dermagraft
• Epicel
• Gintuit
• Grafix
• Holoderm
• Kaloderm
• KeraHeal/KeraHeal-Allo
• LaViv
• Orcel
• Quencell
• RECELL
• Rosmir
• Stravix
• TransCyte
  • Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
  • Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2019

Trends in Research and Development

• • Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
• • Table 3-4: Dermatology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)

Market Breakdown of Cell and Gene Therapies

• • Table 3-5: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
• • Figure 3-3: Dermatology Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Stem cells, Skin cells)
• • Figure 3-4: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Stem cells, Skin cells)
• Dermatology Cell and Gene Therapy Market by Indication
  • Table 3-6: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
  • Figure 3-5: Dermatology Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Wound healing/treatment, Others [wrinkles, scar treatment])

Regional Market Summary

• • Figure 3-6: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, Canada, Australia/New Zealand, Japan, China, Other countries)
• • Table 3-7: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
• • Figure: 3-7: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries [Australia, Canada, China, Singapore, etc.])

Competitor Summary

• • Table 3-8: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

Chapter 4: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
Overview

• Cardiovascular Disease
• Selected Blood Disorders

Market Outlook

• • Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2019-2030 ($ millions)

Principal Products

• Collategene
• Hearticellgram
• HeartSheet
• Neovasculgen
• Stempeucel
• Zynteglo
• Cord Blood Products
  • Table 4-1: Cell and Gene Therapy in Cardiovascular and Blood Disorders
  • Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2019

Trends in Research and Development

• • Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase (%), March 2020 Data
• • Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
• Phase III Development
  • Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through March 2020
• Orphan Drug, Fast Track, Breakthrough Designations
  • Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through March 2020

Market Breakdown of Cell and Gene Therapies

• • Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
• • Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Stem cells, Other cell therapy, Gene therapy, Stromal cells)
• • Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Gene therapy, Stem cells, Other cell therapy, Stromal cells)
• Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
  • Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Figure 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Figure 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication (wound healing/treatment vs. other indications), Estimated 2020 (%) (Blood disorders, Cardiac disorders, Vascular disorders, Hypercholesterolemia)

Regional Market Summary

• • Figure 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, India, Japan, Other countries)
• • Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Japan, Other countries)
• • Figure 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)

Competitor Summary

Chapter 5: Cell and Gene Therapy Markets in Oncology
Overview

• Biochemistry of Cancer Cells

Causes of Cancer Growth

• Environmental Factors, DNA, RNA
  • Table 5-1: Virus Association with Human Cancer
• Cellular Oncogenes
• Tumor Suppressor Genes
• CAR-T Therapies

Global Cancer Burden

• • Figure 5-1: Global Cancer Incidence Trends, 2010-2040
• • Figure 5-2: Incidence of Cancer by Type, 2018 (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder)
• • Figure 5-3: Distribution of Cancer Incidence by Type, 2018 (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder, Others)

Market Outlook

• • Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2019-2030 ($ millions)

Principal Products

• APCeden
• CreaVax-RCC
• Gendicine
• Imlygic
• Immuncell-LC
• Kymriah
• Provenge
• Yescarta
• Zalmoxis
  • Table 5-2: Cell and Gene Therapy in Oncology
  • Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2019

Trends in Research and Development

• • Table 5-3: Oncology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
• • Table 5-4: Oncology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
• • Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, March 2020 Data (Phase I through Phase III) (Anal, Bladder, Brain, Breast, Cancer [unspecified], Cervical, Colorectal, Head & Neck, Hematologic [leukemia and general], Liver, Lung, Lymphoma, Melanoma, Multiple Myeloma, Other, Ovarian, Pancreatic, Prostate, Renal, Solid Tumors)
• Phase III Development
  • Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through March 2020
• Orphan Drug, Fast Track, Breakthrough Designations
  • Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020

Market Breakdown of Cell and Gene Therapies

• • Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
• • Figure 5-7: Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
• • Figure 5-8: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
• Oncology Cell and Gene Therapy Market by Cancer Type
  • Table 5-8: Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
  • Figure 5-9: Oncology Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Blood cancers [lymphoma, leukemia], Prostate cancer, Melanoma, Other cancer)
  • Figure 5-10: Oncology Cell and Gene Therapy Market by General Indication (Blood cancers, Prostate cancer, Melanoma, Other cancers), Estimated 2020 (%)

Regional Market Summary

• • Figure 5-11: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, Other countries)
• • Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Other countries)
• • Figure: 5-12: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)

Competitor Summary

• • Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

Chapter 6: Cell and Gene Therapy Markets in Ophthalmic Conditions
Overview
Market Outlook

• • Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2019-2030 ($ millions)

Principal Products

• Holoclar
• Luxturna
  • Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions

Trends in Research and Development

• • Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
• • Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified cell)
• Phase III Development
  • Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through March 2020
• Orphan Drug, Fast Track, Breakthrough Designations
  • Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020

Market Breakdown of Cell and Gene Therapies

• • Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
• • Figure 6-2: Ophthalmology Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
• • Figure 6-3: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Stem cells, Gene therapy, Other cell therapy)

Regional Market Summary

• • Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Other countries)
• • Figure: 6-4: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)

Competitor Summary

Chapter 7: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
Overview
Market Outlook

• • Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 2019-2030 ($ millions)

Principal Products

• AlloStem
• BIO4
• Carticel
• Cartiform
• CartiLife
• Cartistem
• ChondroCelect
• Chondron
• JACC
• MACI
• Ortho-ACI and Ortho-ATI
• Ossron
• Osteocel and Osteoplus
• Spherox
• Trinity Elite and Trinity Evolution
  • Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
  • Figure 7-2: Musculoskeletal Cell Therapy Approvals by Year or Year Range, through 2019

Trends in Research and Development

• • Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase (%), March 2020 Data
• • Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified cell)

Market Breakdown of Cell Therapies

• • Table 7-4: Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
• • Figure 7-3: Musculoskeletal Cell Therapy Market, 2017 – 2030 ($ millions)
• Musculoskeletal Cell Therapy Market by Indication
  • Table 7-5: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Figure 7-4: Musculoskeletal Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Figure 7-5: Musculoskeletal Cell Therapy Market by General Indication (Cartilage treatment, Bone treatment and Other indications), Estimated 2020 (%) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])

Regional Market Summary

• • Figure 7-6: Musculoskeletal Cell Therapy Approvals by Country/Region (%), through 2019 (United States, Europe/European Union, Other countries)
• • Table 7-6: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
• • Figure: 7-7: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries [Australia, Japan, Canada, India])

Competitor Summary

• • Table 7-7: Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

Chapter 8: Cell and Gene Therapy Markets in Other Conditions
Overview
Market Outlook

• • Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2019-2030 ($ millions)

Principal Products

• Alofisel
• Cupistem
• Givlaari
• Glybera
• NeuroNata-R
• Onpattro
• Stemirac
• Strimvelis
• Temcell/Prochymal
• Zolgensma
  • Table 8-1: Cell and Gene Therapy in Other Diseases and Disorders

Trends in Research and Development

• • Table 8-2: Other Conditions and Disorders: Cell and Gene Therapies in Development by Segment and Phase (%), March 2020 Data (ALS, Alzheimer’s disease, Autoimmune diseases, Diabetes, Fabry’s disease, HIV, Immune/transplant, Infectious diseases (excluding HIV), Liver disease, Multiple sclerosis, Muscular dystrophy, Other conditions (not categorized), Other genetic (not listed), Other neurological (not listed), Parkinson’s disease, PKU, Pompe disease, Renal disease, Respiratory diseases, Spinal cord injury, Traumatic brain injury, Urological disorders)

Market Breakdown of Cell and Gene Therapies

• • Table 8-3: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
• • Figure 8-2: Other Conditions Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
• • Figure 8-3: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Cell therapy, Gene therapy, Gene-modified cell therapy)

Regional Market Summary

• • Table 8-4: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
• • Figure 8-4: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries)

Competitor Summary

Chapter 9: Cell and Gene Therapy Market Review
Market Influences

• Global Demographics
  • Table 9-1: Global Population, through 2050 (population in millions)
  • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
• Cost Containment
  • Table 9-2: Cost Comparisons for Commercialized Cell and Gene Therapies

Global Market Summary

• • Table 9-3: Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)

Cell vs. Gene Therapy Markets

• • Table 9-4: Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)

Regional Market Overview

• • Table 9-5: Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)

United States

• • Table 9-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
• • Figure 9-2: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
• • Table 9-7: Major Cell and Gene Therapy Product Approvals, FDA

Europe/European Union

• • Table 9-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
• • Figure 9-3: Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
• • Table 9-9: Major Cell and Gene Therapy Approvals by EMA

Other Countries

• • Table 9-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
• • Figure 9-4: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
• • Table 9-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

Competitor Ranking in Cell and Gene Therapy Markets

• • Table 9-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)

Chapter 10: Market Participants
Leading Influencers
Advantagene, Inc.

• • Table 10-1: Advantagene Corporate Summary
• Company Summary
• Products

Advaxis, Inc.

• • Table 10-2: Advaxis Corporate Summary
• Company Summary
• Products

AlloSource

• • Table 10-3: AlloSource Corporate Summary
• Company Summary
• Products

Alnylam Pharmaceuticals

• • Table 10-4: Alnylam Pharmaceuticals Corporate Summary
• Company Summary
• Products

Amgen

• • Table 10-5: Amgen Corporate Summary
• Company Summary
• Products

AnGes Inc.

• • Table 10-6: AnGes Corporate Summary
• Company Summary
• Products

Anterogen Co Ltd.

• • Table 10-7: Anterogen Corporate Summary
• Company Summary
• Products

Atara Biotherapeutics

• • Table 10-8: Atara Biotherapeutics Corporate Summary
• Company Summary
• Products

Athersys, Inc

• • Table 10-9: Athersys Corporate Summary
• Company Summary
• Products

AveXis, Inc.

• • Table 10-10: AveXis Corporate Summary
• Company Summary
• Products

BioCardia

• • Table 10-11: BioCardia Summary
• Company Summary
• Products

Biogen, Inc.

• • Table 10-12: Biogen Corporate Summary
• Company Summary
• Products

BioMarin Pharmaceuticals

• • Table 10-13: BioMarin Pharmaceuticals Corporate Summary
• Company Summary
• Products

bluebird bio, Inc.

• • Table 10-14: bluebird bio Corporate Summary
• Company Summary
• Products

Brainstorm Cell Therapeutics

• • Table 10-15: Brainstorm Cell Therapeutics Corporate Summary
• Company Summary
• Products

Caladrius Biosciences

• • Table 10-16: Caladrius Biosciences Corporate Summary
• Company Summary
• Products

Celyad

• • Table 10-17: Celyad Corporate Summary
• Company Summary
• Products

Cook Myosite, Inc

• • Table 10-18: Cook Myosite Corporate Summary
• Company Summary
• Products

Cytori Therapeutics, Inc

• • Table 10-19: Cytori Therapeutics Corporate Summary
• Company Summary
• Products

Dendreon Pharmaceuticals LLC

• • Table 10-20: Dendreon Corporate Summary
• Company Summary
• Products

Ferring Pharmaceuticals

• • Table 10-21: Ferring Pharmaceuticals Corporate Summary
• Company Summary
• Products

Fibrocell (Castle Creek Biosciences)

• • Table 10-22: Fibrocell Corporate Summary
• Company Summary
• Products

Gamida Cell Ltd.

• • Table 10-23: Gamida Cell Corporate Summary
• Company Summary
• Products

GenSight Biologics S.A.

• • Table 10-24: GenSight Biologics Corporate Summary
• Company Summary
• Products

Gilead Sciences, Inc.

• • Table 10-25: Gilead Sciences Corporate Summary
• Company Summary
• Products

Gradalis, Inc

• • Table 10-26: Gradalis Corporate Summary
• Company Summary
• Products

Inovio Pharmaceuticals, Inc.

• • Table 10-27: Inovio Pharmaceuticals Corporate Summary
• Company Summary
• Products

Kiadis Pharma B.V.

• • Table 10-28: Kiadis Pharma Corporate Summary
• Company Summary
• Products

Medeor Therapeutics

• • Table 10-29: Medeor Therapeutics Corporate Summary
• Company Summary
• Products

Medipost Co, Ltd.

• • Table 10-30: Medipost Corporate Summary
• Company Summary
• Products

Merck & Co., Inc.

• • Table 10-31: Merck & Co. Corporate Summary
• Company Summary
• Products

Mesoblast Ltd.

• • Table 10-32: Mesoblast Corporate Summary
• Company Summary
• Products

Moderna, Inc

• • Table 10-33: Moderna Corporate Summary
• Company Summary
• Products

Neurotech Pharmaceuticals, Inc.

• • Table 10-34: Neurotech Corporate Summary
• Company Summary
• Products

Northwest Biotherapeutics, Inc.

• • Table 10-35: Northwest Biotherapeutics Corporate Summary
• Company Summary
• Products

Novartis AG

• • Table 10-36: Novartis Corporate Summary
• Company Summary
• Products

NuVasive Biologics

• • Table 10-37: NuVasive Biologics Corporate Summary
• Company Summary
• Products

Orchard Therapeutics

• • Table 10-38: Orchard Therapeutics Corporate Summary
• Company Summary
• Products

Organogenesis

• • Table 10-39: Organogenesis Corporate Summary
• Company Summary
• Products

Orthofix Medical Inc.

• • Table 10-40: Orthofix Corporate Summary
• Company Summary
• Products

Osiris Therapeutics, Inc.

• • Table 10-41: Osiris Corporate Summary
• Company Summary
• Products

Pharmicell

• • Table 10-42: Pharmicell Corporate Summary
• Company Summary
• Products

Pluristem Therapeutics, Inc.

• • Table 10-43: Pluristem Therapeutics Corporate Summary
• Company Summary
• Products

Quark Pharmaceuticals

• • Table 10-44: Quark Pharmaceuticals Corporate Summary
• Company Summary
• Products

Regenerative Medical System

• • Table 10-45: Regenerative Medical Corporate Summary
• Company Summary
• Products

Renova Therapeutics

• • Table 10-46: Renova Therapeutics Corporate Summary
• Company Summary
• Products

Sangamo Therapeutics

• • Table 10-47: Sangamo Therapeutics Corporate Summary
• Company Summary
• Products

Sanofi

• • Table 10-48: Sanofi Corporate Summary
• Company Summary
• Products

SOTIO a.s.

• • Table 10-49: SOTIO Corporate Summary
• Company Summary
• Products

Spark Therapeutics

• • Table 10-50: Spark Therapeutics Corporate Summary
• Company Summary
• Products

Tessa Therapeutics, Ltd.

• • Table 10-51: Tessa Therapeutics Corporate Summary
• Company Summary
• Products

Tocagen, Inc.

• • Table 10-52: Tocagen Corporate Summary
• Company Summary
• Products

uniQure N.V.

• • Table 10-53: uniQure Corporate Summary
• Company Summary
• Products

VBL Therapeutics (Vascular Biogenics Ltd.)

• • Table 10-54: VBL Therapeutics Corporate Summary
• Company Summary
• Products

Vericel Corporation

• • Table 10-55: Vericel Corporate Summary
• Company Summary
• Products

ViroMed Co Ltd (Helixmith)

• • Table 10-56: ViroMed Corporate Summary
• Company Summary
• Products